Genprex Issues April 2020 Shareholder Letter

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it has issued an April 2020 Shareholder Letter. The letter highlights the Company’s progress with Oncoprex, its lead drug candidate with an initial targeted indication for non-small cell lung cancer (NSCLC), its license agreement for a diabetes gene therapy drug candidate, and other operational and business achievements.

Recent Company Highlights Include:

• Receiving Fast Track Designation from the Food and Drug Administration (FDA) for Oncoprex in combination with osimertinib (AstraZeneca’s Tagrisso) for the treatment of patients with NSCLC
• Signing an exclusive license agreement with the University of Pittsburgh for a preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes
• Obtaining encouraging preclinical data from research collaborators and independent third parties with the TUSC2 gene, the active agent in Oncoprex, in lung cancer and triple-negative breast cancer
• Raising more than $26 million in gross proceeds from institutional investors in three separate equity offerings

To read the letter in its entirety, view a digital copy of the Company’s Shareholder Letter, which can be found on the Company’s website here.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, Oncoprex, is being evaluated as a treatment for non-small cell lung cancer (NSCLC). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso). For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.